|
- Rajesh T, Gandhi M.D, Martin Hirsch M.D, et al. Treating Acute Covid-19. Final Chapters Still Unwritten. N Engl J Med. 2024 April 4. DOI: 10.1056/NEJMe2401743.
- Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2118542. https://www.nejm.org/doi/pdf/10.1056%2FNEJMoa2118542
- Consultar documento sobre uso de Remdesivir: https://covid19.seimc.org/index.php/papel-del-remdesivir-en-pacientes-con-covid-19/
- Consultar documento sobre uso de Ac monoclonales. https://covid19.seimc.org/index.php/papel-de-los-anticuerpos-monoclonales-en-pacientes-con-covid-19/
- Folgueira MD, Luczkowiak J, Lasala F, Pérez-Rivilla A, Delgado R. Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19. Clin
Microbiol Infect. 2021 Jun;27(6):886-891. doi: 0.1016/j.cmi.2021.02.014
- Amstutz A, Speich B, Mentré F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. The Lancet Respiratory Medicine [Internet] 2023 [cited 2023 Feb 23];0(0). Available from: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00528-8/fulltext#%20
- Consultar documento sobre uso de esteroides: https://covid19.seimc.org/index.php/papel-de-los-corticosteroides-en-pacientes-con-covid-19/ La OMS (https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1).
- Consultar documento sobre uso de Tocilizumab: https://covid19.seimc.org/index.php/fundamento-del-uso-de-tocilizumab-en-pacientes-con-covid-beneficio-vs-riesgo/
- https://www.covid-19.seth.es/wp-content/uploads/2020/04/Recomendaciones-tromboprofilaxis-y-tratamiento-antitrombotico-pacientes-COVID-19_2020-04-29.pdf
- The REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19. N Engl J Med 2021; 384: 1491–502. https://www.nejm.org/doi/full/10.1056/nejmoa2100433
- Kalil, A.C., et al. Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19. New England Journal of Medicine, 384(9), 795–807. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2031994.
- Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med [Internet] 2021 [cited 2021 Sep 5]; Available from: https://www.nature.com/articles/s41591-021-01499-z
- IDSA Guidelines on the Treatment and Managements of Patients with Covid-19.
- Frost J, Gornicec M, Reisinger AC, el tal. COVID-19 associated Pulmonary Aspergilosis inPatients Admitted to th Intensive Care Unit: Impacto f Antifungical Prophylaxis. Mycopathología 2024, 189:3.
|
